secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061077
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q3 2023: $350M cash, multiple IND clearances, FT522 enrollment started
--------------------------------------------------------------------------------

- Cash, cash equivalents & investments $349.7M as of Sept 30, 2023; runway into 2H25.
- Revenue $1.9M from ONO collaboration; GAAP operating expenses $53.2M (R&D $34.3M, G&A $18.9M).
- FT522 Phase 1 open for enrollment in B-cell lymphoma; 3-dose cohort at 300M cells per dose.
- IND cleared for FT825/ONO-8250 CAR T targeting HER2 in solid tumors; Phase 1 start-up ongoing.
- IND cleared for FT819 CAR T in systemic lupus erythematosus; Phase 1 design includes single dose with preconditioning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023061077/0000950170-23-061077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023061077/fate-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer